Fadi Haddad: Hyperleukocytosis in Acute myeloid leukemia
Fadi Haddad, Assistant Professor at Leukemia Department at MD Anderson Cancer Center, shared a post on X about a recent paper titled “Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis” published in the JCO Oncology Practice.
Authors: Fadi G. Haddad, Koji Sasaki, Jayastu Senapati, Lianchun Xiao, Grace Park, Tareq Abuasab, Sangeetha Venugopal, Daniel Rivera, Alexandre Bazinet, Rodrick Babakhanlou, Kunhwa Kim, Faustine Ong, Sai Desikan, Naveen Pemmaraju, Sanam Loghavi, Gautam Borthakur, Courtney DiNardo, Hussein A. Abbas, Nicholas J. Short, Naval Daver, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Tapan Kadia.
“Out in ASCO’s JCO Oncology Practice Hyperleukocytosis in AML (acute myeloid leukemia)
People: N=129, WBC>100K
MVA = older age, leukostasis, platelets <40 leads to Higher early mortality
- ICU admission needed
- Cytoreductive therapy at measured dosing could reduce complications.”
Source: Fadi Haddad/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023